Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression.
Qamar J. Khan(University of Kansas Medical Center), Priyanka Sharma(Chandigarh University), Anne O’Dea(University of Kansas Medical Center), Jamie L. Wagner(University of Kansas Medical Center), Carol J. Fabian(Washington Hospital), Hung‐Wen Yeh(Children's Mercy Hospital), S Baccaray(The University of Kansas Cancer Center), Michelle Springer(University of Kansas Medical Center), Carol S. Connor(University of Kansas Medical Center), Joshua M.V. Mammen(University of Alaska Anchorage), Marilee McGinness(University of Kansas Medical Center)
Cited by 2
Related Papers
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
American Society of Clinical Oncology Position Statement on Obesity and Cancer
|Journal of Clinical Oncology|2014|524
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
|PubMed|2002|383
(untitled)
|Edinburgh Research Explorer|0|353